comparemela.com

Ran Jin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Strong Satisfaction Levels with Adalimumab Biosimilar Seen Among Initiators, Switchers with IBD

This new analysis on IBD patients initiating biologic therapy with the biosimilar ABP 501 indicates that the drug’s lower cost and efficacy may lead to greater use.

Thousand oaksUnited statesUnited kingdomAmgen incDisease specific programmeRan jinSpecific programmeWork productivityActivity impairmentInflammatory bowel diseaseAbp 101

Study Observes Low Switch Back Rates in Infliximab Biosimilar ABP 710

During the study follow-up period, 74.5% of switchers and 51.3% of infliximab-naïve patients remained on ABP 710 treatment without a treatment gap.

Drug administrationAmgen incRan jinDigestive disease week

vimarsana © 2020. All Rights Reserved.